The objective of this study was to examine the prognostic significance of carbonic anhydrase IX (CAIX), an endogenous marker for tumor hypoxia; the cellular tumor antigen p53; and the apoptosis regulator Bcl-2, in triple-negative breast cancer (TNBC) patients.
Immunohistochemically determined expression of CAIX, p53, Bcl-2 and proliferation factor Ki-67, analyzed in 64 paraffin-embedded TNBC tissue samples, was used to assess their relation to clinicopathological variables and prognostic implications for overall survival (OS).
Bcl-2 expression was negatively correlated with histological grade of tumor, while expression of p53 was positively correlated with the same clinical variable (p = 0.036 and p = 0.033, respectively). The p53 expression was also positively correlated with tumor size (p = 0.010). Survival analysis showed that patients with high Bcl-2 expression (above cutoff value determined by receiver operator characteristic [ROC] curve analysis) had shorter OS (p = 0.020). The same was observed for patients with tumors larger than 5 cm (p = 0.034) or positive lymph nodes (p = 0.004). Among all 3 examined markers, multivariate analysis showed that only Bcl-2 expression was a strong independent prognostic indicator for decreased OS (hazard ratio [HR] = 15.16, 95% confidence interval [95% CI], 2.881-79.727, p = 0.001).
Elevated expression of Bcl-2 was an independent prognostic factor for poorer OS in TNBC and as such a significant marker for tumor aggressiveness.
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
AuthorsPetar Ozretic, Ilija Alvir, Bozena Sarcevic, Zeljko Vujaskovic, Zrinka Rendic-Miocevic, Ana Roguljic, Lidija Beketic-Oreskovic
- • Accepted on 14/06/2017
- • Available online on 29/07/2017
This article is available as full text PDF.
- Ozretic, Petar [PubMed] [Google Scholar] 1
- Alvir, Ilija [PubMed] [Google Scholar] 2
- Sarcevic, Bozena [PubMed] [Google Scholar] 3
- Vujaskovic, Zeljko [PubMed] [Google Scholar] 4
- Rendic-Miocevic, Zrinka [PubMed] [Google Scholar] 5
- Roguljic, Ana [PubMed] [Google Scholar] 5
- Beketic-Oreskovic, Lidija [PubMed] [Google Scholar] 5, 6, * Corresponding Author (firstname.lastname@example.org)
Laboratory for Hereditary Cancer, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb - Croatia
Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia
Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia
Division of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland - USA
Department of Radiotherapy and Internal Oncology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Center, Zagreb - Croatia
Department of Clinical Oncology, University of Zagreb School of Medicine, Zagreb - Croatia